Nemdatine

Actavis Group PTC ehf,Dalshraun 1,220 Hafnarfjörður,Iceland🇪🇺 European Union

EMA Page

Authorised Date: Apr 22, 2013
Approval ID: f2eb1b76843aa1df
Products: 2 listed
Opinion Adopted: N/A

Overview Summary

This is a summary of the European public assessment report (EPAR) for Nemdatine. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Nemdatine. For practical information about using Nemdatine, patients should read the package leaflet or contact their doctor or pharmacist.

Therapeutic & Classification

Therapeutic Indication

### Therapeutic indication Treatment of patients with moderate to severe Alzheimer’s disease.

Therapeutic Area (MeSH)

N/A

ATC Code

N06DX01

ATC Item

memantine

Pharmacotherapeutic Group

N/A

Active Substances

Active Substance (Summary)

memantine

INN / Common Names

N/A

Active Substance Details

Substance	CAS	Monograph
memantine	N/A	美金刚

Quick Info

Approval IDf2eb1b76843aa1df

Product NumberN/A

StatusAuthorised

Authorised DateApr 22, 2013

Opinion AdoptedN/A

Revision #N/A

Names & Aliases

EMA Name

Nemdatine

Medicine Name

Nemdatine

Aliases

N/A

Regulatory Flags

Orphan medicineUnknown

Generic medicineUnknown

BiosimilarUnknown

Conditional approvalUnknown

Exceptional circumstancesUnknown

Accelerated assessmentUnknown

Additional monitoringUnknown

Advanced therapyUnknown

Source Links

EMA Source

No risk management plan link.

Back to EMA Approvals